The company’s lead candidate, ET-01, is currently in preclinical development for the treatment of Friedreich’s Ataxia, a debilitating genetic disease. The potential of ET-01, along with the company’s other drug candidates, has contributed to the positive performance of NASDAQ:TRDA
Saturday, July 22, 2023
Understanding the Impact of Entrada Therapeutics Inc. on NASDAQ:TRDA
JUL 22, 2023. CORP THESPYWHOBILLEDME. The company’s innovative approach to drug development has been a key factor in its success. Entrada Therapeutics Inc. uses its proprietary Endosomal Escape Vehicle (EEV) technology to develop drugs that can penetrate cells and deliver therapeutic agents directly to the site of disease. Investors have shown a keen interest in Entrada Therapeutics Inc., largely due to the company’s promising drug pipeline.
